慢性肢体威胁性缺血患者中人工血管与生物血管移植物对比手臂静脉移植物的结局
基于VQI数据库2003年1月至2024年4月9165例腹股沟下旁路手术,比较手臂静脉(AV)、人工血管(PG)和生物血管(BG)的结局。与AV相比,PG感染风险更高(aOR 2.89)且1年死亡风险更高(aHR 1.51);BG移植物闭塞(aOR 4.55)、感染(aOR 2.78)、1年死亡(aHR 1.53)、截肢(aHR 1.72)及截肢或死亡(aHR 1.52)风险均更高。AV在膝下腘动脉和胫动脉靶血管中总生存和无截肢生存最佳。
要点
- 与手臂静脉相比,人工血管感染风险更高(aOR 2.89)且1年死亡风险更高(aHR 1.51)。
- 与手臂静脉相比,生物血管移植物闭塞(aOR 4.55)、感染(aOR 2.78)、1年死亡(aHR 1.53)、截肢(aHR 1.72)及截肢或死亡(aHR 1.52)风险更高。
- 无大隐静脉时,手臂静脉和人工血管1年无截肢生存及无主要不良肢体事件生存相当。
核心结论
- 在比较大隐静脉替代移植物的大型多机构研究中,手臂静脉移植物抗感染能力最强,总生存和保肢结局优于人工血管和生物血管移植物,尤其在膝下远端靶血管。
- 无大隐静脉可用时,手臂静脉和人工血管是可接受的替代选择,1年无截肢生存及无主要不良肢体事件生存率相当。
- 与手臂静脉相比,生物血管移植物与更高的移植物闭塞风险及更低的无主要截肢和死亡生存相关。
研究设计与样本
- 查询血管质量倡议(VQI)数据库2003年1月至2024年4月接受腹股沟下旁路手术的患者。
- 按移植物类型分为三组:手臂静脉(头静脉、贵要静脉)417例(4.55%)、人工血管(Dacron、聚四氟乙烯[PTFE])7520例(82.05%)、生物血管(尸体、同种或异种)1228例(13.40%),共9165例手术。
- 排除大隐静脉和小隐静脉移植物。
- 多因素logistic回归分析术后结局:30天死亡、主要不良心血管事件、移植物闭塞、延长住院>7天、输注浓缩红细胞>2单位及感染。
- Cox回归报告1年结局:死亡、主要截肢(踝以上)及主要不良肢体事件(定义为主要截肢、血栓切除或再干预)。
主要发现
- 与手臂静脉相比,人工血管组感染风险更高(aOR 2.89;P = .045),1年死亡风险更高(aHR 1.51;P = .035)。
- 与手臂静脉相比,生物血管组移植物闭塞风险更高(aOR 4.55;P = .040),感染风险更高(aOR 2.78;P = .046)。
- 与手臂静脉相比,生物血管组1年死亡风险更高(aHR 1.53;P = .040),截肢风险更高(aHR 1.72;P = .019),截肢或死亡风险更高(aHR 1.52;P = .005)。
- 按旁路构型分层后,在膝下腘动脉和胫动脉靶血管中,手臂静脉组在三种替代移植物中总生存和无截肢生存最高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The optimal conduit for infrainguinal bypass (IIB) is single-segment great saphenous vein (GSV). Unfortunately, GSV is not always available in patients with chronic limb-threatening ischemia (CLTI). Other graft choices include arm vein grafts (AVs), prosthetic grafts (PGs), or biologic grafts (BGs). Current data regarding the durability and limb salvage rates of those options is scarce; hence, we aimed to investigate the impact of alternative graft types on postoperative and long-term outcomes on IIB in patients with CLTI. METHODS: The Vascular Quality Initiative (VQI) database was queried for patients undergoing IIB from January 2003 to April 2024. Patients were stratified into three groups: AVs (cephalic, basilic), PGs (Dacron, polytetrafluoroethylene [PTFE]), and BGs (cadaveric, homograft, or xenograft). Saphenous vein grafts (greater and lesser saphenous) were excluded. Multivariate logistic regression analyzed postoperative outcomes: 30-day mortality, major adverse cardiovascular events, graft occlusion, prolonged length of stay >7 days, packed red blood cell transfusion >2 units, and infection. Cox regression was used to report 1-year outcomes: mortality, major amputation (above-ankle), and major adverse limb events (defined as major amputation, thrombectomy, or reintervention). RESULTS: A total of 9165 IIB procedures have been analyzed: AV, 417 (4.55%); PG, 7520 (82.05%); and BG, 1228 (13.40%). Compared with AVs, patients receiving PGs had higher odds of infection (adjusted odds ratio [aOR], 2.89; P = .045) and higher hazard of 1-year mortality (adjusted hazard ratio [aHR], 1.51; P = .035). On the other hand, patients receiving BGs had higher risk of graft occlusion (aOR, 4.55; P = .040) and infection (aOR, 2.78; P = .046), as well as higher hazard of 1-year mortality (aHR, 1.53; P = .040), amputation (aHR, 1.72; P = .019), and amputation or death (aHR, 1.52; P = .005) compared with patients receiving AVs. After stratifying by bypass configuration, patients with AVs had the highest overall survival and amputation-free survival among the three alternative conduits in below-knee popliteal and tibial bypass targets. CONCLUSIONS: In this large multi-institutional study investigating alternative conduits to GSV, AVs are found to be the most resistant to infections and are associated with the best overall survival and limb salvage outcomes compared with PGs and BGs, particularly in below-knee distal targets. In cases where no GSV is available, AVs and PGs are acceptable alternatives with comparable 1-year amputation-free survival and major adverse limb events-free survival rates. On the other hand, BGs are associated with higher risk of graft occlusion and lower freedom from major amputation and death compared with AVs.
引用
- Hamouda M, Zarrintan S, Vootukuru N, et al. Outcomes of prosthetic and biological grafts compared to arm vein grafts in patients with chronic limb-threatening ischemia. J Vasc Surg. 2024. PMID: 39490459. doi:10.1016/j.jvs.2024.10.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。